Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8552
Name chronic myeloid leukemia
Definition A myeloid leukemia that is characterized by over production of white blood cells.
Source DiseaseOntology.org
Alt Ids DOID:8551 DOID:8606
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia chronic myeloid leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00129740 Phase II Nilotinib Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) Completed USA 0
NCT00471497 Phase III Nilotinib Imatinib A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 25
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00573378 Phase II Imatinib + Interferon alpha-2b Interferon alpha-2b + Nilotinib Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia Terminated USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00679536 Phase Ib/II anti-thymocyte globulin + Busulfan + Fludarabine Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Unknown status USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00777036 Phase II Dasatinib A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT01077544 Phase I Nilotinib A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) Completed NLD | ITA | GBR | FRA 0
NCT01188889 Phase Ib/II Everolimus + Imatinib RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease Withdrawn USA 0
NCT01244750 Phase I Imatinib Dasatinib Nilotinib Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Completed USA | NLD | ITA | FRA | ESP | DEU 2
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01397734 Phase I Arsenic trioxide Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Terminated USA 0
NCT01498445 Phase Ib/II Dasatinib + Decitabine An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Terminated USA 0
NCT01570868 Phase II Ponatinib Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Terminated USA 0
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Active, not recruiting USA | ITA | FRA | BEL 2
NCT01593254 Phase II Imatinib Dasatinib Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) Completed USA | ITA | FRA | ESP | CAN | BEL | AUT 8
NCT01606579 Phase Ib/II Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724 Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies Completed USA 0
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated USA 0
NCT01634217 Phase I Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Completed USA 0
NCT01640301 Phase Ib/II Aldesleukin WT1 sensitized T cells Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Terminated USA 0
NCT01660906 Phase III Dasatinib This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed USA | ITA | FRA | DEU 1
NCT01698905 Phase II Nilotinib Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop) Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT01702064 Phase I Nilotinib + Ruxolitinib Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Completed USA 0
NCT01744665 Phase II Nilotinib Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5. (ENESTgoal) Completed USA 0
NCT01746836 Phase II Ponatinib Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib Recruiting USA 0
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting USA 0
NCT01751425 Phase II Ruxolitinib Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Terminated USA 0
NCT01776723 Phase II Ruxolitinib A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Completed USA 0
NCT01784068 Phase II Nilotinib Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT 10
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT01823198 Phase Ib/II Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies Completed USA 0
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated USA 1
NCT01844765 Phase II Nilotinib Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Completed USA | NLD | ITA | GBR | FRA | ESP 7
NCT01850004 Phase II Dasatinib Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Completed USA | ITA | FRA | ESP | DEU | CAN 0
NCT01885897 Phase Ib/II Nogapendekin alfa inbakicept IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Completed USA 0
NCT01892371 Phase Ib/II Azacitidine + Quizartinib Cytarabine + Quizartinib Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT01903733 Phase I Bosutinib Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 Completed USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUS 20
NCT01914484 Phase II Nilotinib + Ruxolitinib Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Completed CAN 0
NCT01926587 Phase Ib/II Azacitidine + Regorafenib Oral Rigosertib in Combination With Azacitidine Completed USA | FRA 0
NCT02011945 Phase I Dasatinib + Nivolumab A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia Completed USA | ITA | FRA | ESP | DEU | CAN | AUS 0
NCT02047149 Phase I Dasatinib + Zileuton Evaluating the Safety of Zileuton (Zyflo(R)) in Combination With Dasatinib (Sprycel (R) in Chronic Myelogenous Leukemia Terminated USA 0
NCT02081378 Phase I Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL Completed USA | NLD | ITA | FRA | ESP | DEU | AUS 3
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting USA 0
NCT02092324 Phase II Ruxolitinib Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Completed USA 0
NCT02115295 Phase II Cladribine + Cytarabine + Idarubicin Midostaurin Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting USA 0
NCT02130557 Phase III Bosutinib Imatinib A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 16
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02225574 Phase Ib/II Binimetinib + Nilotinib An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) Terminated USA 0
NCT02228382 FDA approved Bosutinib Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Terminated USA | ITA | FRA | ESP | DEU | AUT 2
NCT02268370 Phase II Dasatinib Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD) Unknown status CAN 0
NCT02311998 Phase Ib/II Bosutinib + Inotuzumab ozogamicin Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Completed USA 0
NCT02326311 Phase III Dasatinib Nilotinib Imatinib Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients >=60 Years in Deep Molecular Response Recruiting ITA 0
NCT02353728 Phase II Nilotinib Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy Completed USA 0
NCT02381548 Phase I Adavosertib + Belinostat Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Terminated USA 0
NCT02467270 Phase II Ponatinib Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 13
NCT02487459 Phase I Rivogenlecleucel Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Active, not recruiting USA 0
NCT02556931 Phase II Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed USA 0
NCT02602314 FDA approved Imatinib Nilotinib Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM) Unknown status NLD | ITA 0
NCT02629692 Phase Ib/II K0706 Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies Active, not recruiting USA | ITA | GBR | FRA | ESP | BEL 6
NCT02689440 Phase II Dasatinib + Venetoclax Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia Active, not recruiting USA 0
NCT02709083 Phase II Dasatinib Nilotinib Imatinib Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Terminated USA 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02730195 Phase II Pioglitazone Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia Terminated USA 0
NCT02730312 Phase I Vibecotamab PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Completed USA 0
NCT02759016 Phase I BI 836826 + Ibrutinib Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib Completed USA 0
NCT02767063 Phase Ib/II Avelumab Pioglitazone Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW) Unknown status FRA 0
NCT02782403 Phase Ib/II Axitinib + Bosutinib Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia Terminated USA 0
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting USA 0
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Terminated USA 0
NCT02890758 Phase I Nogapendekin alfa inbakicept Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02890784 Phase III Dasatinib Dasatinib Holiday for Improved Tolerability (DasaHIT) Completed DEU 0
NCT02906696 Phase II Bosutinib Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML) Terminated USA 0
NCT02917720 Phase II Nilotinib 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT) Active, not recruiting NLD | DEU 0
NCT02923986 Phase Ib/II BP1001 + Dasatinib Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS Withdrawn USA 0
NCT02930109 Phase Ib/II Cytarabine + Triciribine A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Completed USA 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT02973711 Phase Ib/II Nilotinib + Ruxolitinib A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Withdrawn USA 0
NCT03075826 Phase II Guadecitabine A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Completed USA 0
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03106779 Phase III Bosutinib Asciminib Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 16
NCT03193281 Phase II Imatinib Dasatinib KISS Study: Kinase Inhibition With Sprycel Start up (KISS) Active, not recruiting NZL 0
NCT03267186 Phase II Ibrutinib Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Completed USA 0
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Suspended USA 0
NCT03386513 Phase Ib/II IMGN632 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT03414450 Phase I Dasatinib + ETC-1907206 Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies Withdrawn USA 1
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03516279 Phase II Nilotinib + Pembrolizumab Dasatinib + Pembrolizumab Imatinib + Pembrolizumab Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Recruiting USA 0
NCT03531736 Phase I Rituximab Cyclophosphamide + Fludarabine T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Active, not recruiting USA 0
NCT03573596 Phase II Dasatinib Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment (DASTOP2) Unknown status NLD | FRA | DEU 4
NCT03576547 Phase Ib/II Dexamethasone + Ponatinib + Rituximab + Venetoclax Dexamethasone + Ponatinib + Venetoclax Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Active, not recruiting USA 0
NCT03578367 Phase II Imatinib Nilotinib Asciminib + Imatinib Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 7
NCT03595917 Phase I Asciminib + Blinatumomab + Dasatinib + Prednisone ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Recruiting USA 0
NCT03610971 Phase II Nilotinib + Ruxolitinib Imatinib + Ruxolitinib Bosutinib + Ruxolitinib Dasatinib + Ruxolitinib Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Recruiting USA 0
NCT03654768 Phase II Bosutinib Dasatinib Nilotinib Dasatinib + Ruxolitinib Bosutinib + Ruxolitinib Nilotinib + Ruxolitinib Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia Active, not recruiting USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Withdrawn 0
NCT03807063 Phase I Rimiducid Rivogenlecleucel Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03807479 Phase II Ponatinib Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy (PONS) Terminated DEU 0
NCT03874858 Phase II Nilotinib Asciminib + Nilotinib De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE) Active, not recruiting ITA 0
NCT03895671 Phase II Azacitidine + Ponatinib PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS (PONAZA) Recruiting FRA 0
NCT03906292 Phase II Asciminib + Nilotinib Asciminib + Imatinib Asciminib + Dasatinib Frontline Asciminib Combination in Chronic Phase CML (CMLXI) Active, not recruiting DEU 0
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting NLD | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT04043676 Phase II Ponatinib Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia Unknown status ESP 0
NCT04070443 Phase II Imatinib + Ponatinib Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (TIPI) Active, not recruiting FRA 0
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Active, not recruiting USA | NLD 0
NCT04160546 Phase II Aspirin + Ponatinib Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) (ResToP) Active, not recruiting ESP 0
NCT04188405 Phase II Decitabine + Ponatinib + Venetoclax Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Active, not recruiting USA 0
NCT04216563 Phase II Asciminib ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor Active, not recruiting USA 0
NCT04258943 Phase Ib/II Bosutinib Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Active, not recruiting USA 0
NCT04260022 Phase I HQP1351 Study of HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (HQP1351CU101) Recruiting USA 0
NCT04518644 Expanded access Nilotinib Nilotinib, for Patients With CML-CP or CML-AP No longer available 0
NCT04666259 Phase III Asciminib Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML) Active, not recruiting USA 0
NCT04681105 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Active, not recruiting USA 0
NCT04709731 Phase II Ponatinib Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia (CarPAs) Not yet recruiting ITA 0
NCT04793399 Phase Ib/II Atezolizumab + Bosutinib Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients Terminated ESP 0
NCT04835584 Phase Ib/II Dasatinib + KRT-232 KRT-232 + Nilotinib KRT-232 and TKI Study in Chronic Myeloid Leukemia Recruiting USA | ITA | FRA | ESP | CAN 3
NCT04838041 Phase II Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Recruiting USA 0
NCT04877522 FDA approved Asciminib Bosutinib Dasatinib Nilotinib Asciminib + Imatinib Asciminib Roll-over Study Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 17
NCT04925479 Phase Ib/II Asciminib Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia Recruiting USA | NLD | ITA | FRA | DEU 9
NCT04948333 Phase III Asciminib Asciminib Treatment Optimization in >= 3rd Line CML-CP. Active, not recruiting ITA | GBR | FRA | ESP | DEU | CAN | AUT 9
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Recruiting USA 0
NCT04971226 Phase III Asciminib Bosutinib Imatinib Dasatinib Nilotinib A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT05007873 Phase II Dasatinib + Decitabine and Cedazuridine ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase Recruiting USA 0
NCT05016947 Phase I Dexamethasone + Inotuzumab ozogamicin + Venetoclax Venetoclax Plus Inotuzumab for B-ALL Recruiting USA 0
NCT05143840 Phase II Asciminib Asciminib + Nilotinib Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML) Recruiting USA 0
NCT05177211 Phase II Fedratinib Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) Recruiting USA 0
NCT05178342 Phase II CA-4948 Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS) Recruiting DEU 0
NCT05304377 Phase I ELVN-001 A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (CML) Recruiting USA | FRA | ESP | DEU | AUS 1
NCT05362773 Phase I MGD024 A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies Recruiting USA 0
NCT05384587 Phase II Asciminib Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE) Recruiting USA 0
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Suspended USA 0
NCT05413915 Phase III Asciminib + Imatinib Imatinib Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Recruiting CAN 0
NCT05442515 Phase Ib/II CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT05456191 Phase III Asciminib Nilotinib A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (>=18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START) Recruiting USA | NLD | ITA | GBR | FRA | DEU | CAN 17
NCT05701215 Phase II Venetoclax Venetoclax After TKI to Target Persisting Stem Cells in CML (VARIANT) Recruiting DEU 0
NCT05823571 Phase I Itacitinib Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Recruiting USA 0
NCT06088888 Phase I TGRX-678 TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia Not yet recruiting USA 0
NCT06163430 Phase I TERN-701 CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia Not yet recruiting USA 0
NCT06236724 Phase II Asciminib Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Recruiting USA 0
NCT06291987 Phase I Ivosidenib + Ruxolitinib Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs (MPN) Not yet recruiting USA 0